Neuroscience

Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research

Professional services, Health, Medical devices, Infectious diseases, Finance, General Health, Biotechnology, Branches of biology, Neuroscience, Neurophysiology, Neurotechnology, Autonomic nervous system, Neuromodulation, Neuropsychology, ElectroCore, Vagus nerve, Peter Staats
Wednesday, February 24, 2021 - 12:45pm

Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress.

Key Points: 
  • Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress.
  • In fact, the most downloaded 2020 article in the Journal of Neuromodulation was The Use of Noninvasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID19: A Theoretical Hypothesis and Early Clinical Experience .
  • Research should be focused on identifying novel therapies with strong clinical rationale that can be used throughout the course of disease.
  • electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology.

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

Branches of biology, Neurological disorders, Biology, Life sciences, Neurodegeneration, Neuroscience, Senescence, Eli Lilly and Company, TAR DNA-binding protein 43
Wednesday, February 24, 2021 - 12:00pm

The presentations will highlight preclinical results from the Companys wholly-owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) for neurodegenerative diseases.

Key Points: 
  • The presentations will highlight preclinical results from the Companys wholly-owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) for neurodegenerative diseases.
  • The presentations will showcase how AC Immunes expertise in discovery, assay development and characterization of promising candidates powers its industry-leading pipeline.
  • AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.
  • It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

Neuromorphic Computing Opportunity Analysis 2020: Leveraging Fabrication Technologies, Embedded Memories, SoCs and FPGAs for Developing Solutions in Neuromorphic Computing

Artificial intelligence, Electrical engineering, Neuromorphic engineering, Neuroscience, Robotics, Hardware acceleration, Academic disciplines, Field-programmable gate array, Technology, Science and technology
Tuesday, February 23, 2021 - 6:45pm

DUBLIN, Feb. 23, 2021 /PRNewswire/ -- The "Neuromorphic Computing: Opportunity Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 23, 2021 /PRNewswire/ -- The "Neuromorphic Computing: Opportunity Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, with increasing demand for fully autonomous solutions, there is a need for perceptive solutions capable of making probabilistic decisions, replicating the human brain.
  • What are the current trends and developments that are driving the opportunities for neuromorphic computing technologies in the global market?
  • 3.12 Analysis of Value Chain - Leveraging Fabrication Technologies, Embedded Memories, SoCs and FPGAs for Developing Solutions in Neuromorphic Computing
    4.3 Analysis of Applications Impacted by Neuromorphic Computing - Robotics, Manufacturing, Security and Surveillance
    4.4 Analysis of Applications Impacted by Neuromorphic Computing - Home Automation, Retail, Banking and Finance
    4.5 Analysis of Applications Impacted by Neuromorphic Computing - Automotive, Energy, Aerospace and Defence

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Branches of biology, Neuroscience, Neurophysiology, Electrophysiology, Brain–computer interfacing, Electrodiagnosis, Neurotechnology, Electroencephalography, Draft:Wireless EEG, Brain–computer interface
Tuesday, February 23, 2021 - 6:33pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Branches of biology, Neuroscience, Neurophysiology, Electrophysiology, Brain–computer interfacing, Electrodiagnosis, Neurotechnology, Electroencephalography, Draft:Wireless EEG, Brain–computer interface
Tuesday, February 23, 2021 - 6:16pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares

Branches of biology, Financial markets, Neuroscience, Depositary receipts, Equity securities, Brainsway, Neurophysiology, Neuropsychology, Treatment of depression, American depositary receipt, Tel Aviv Stock Exchange
Tuesday, February 23, 2021 - 1:30pm

CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced it has priced an underwritten public offering of4,622,000 American Depositary Shares, each representing two ordinary shares, at an offering price of$8.50 per American Depositary Share.

Key Points: 
  • CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced it has priced an underwritten public offering of4,622,000 American Depositary Shares, each representing two ordinary shares, at an offering price of$8.50 per American Depositary Share.
  • The gross proceeds from the offering will be approximately $39,287,000, before deducting underwriting discounts and commissions and estimated offering expenses.
  • BrainsWay has also granted the underwriters a 30-day option to purchase up to an additional693,300 American Depositary Shares on the same terms and conditions.
  • The closing of the offering is expected to take place on February 25, 2021, subject to the satisfaction of customary closing conditions.

NeuroStar® Advanced Therapy Outcomes Registry Clinical Data Published in Brain Stimulation Validates Depression Treatment Protocols

Branches of biology, Medicine, Neurotechnology, Neuroscience, Electrotherapy, Medical devices, Neurophysiology, Transcranial magnetic stimulation, Treatment of depression, Management of depression, Major depressive disorder, Todd M. Hutton
Tuesday, February 23, 2021 - 1:00pm

The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive transcranial magnetic stimulation (TMS) option for treating depression.

Key Points: 
  • The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive transcranial magnetic stimulation (TMS) option for treating depression.
  • Since its launch, it has grown into the largest registry focused on outcomes for depression treatment.
  • Im grateful to the NeuroStar providers who contribute to the Outcomes Registry; it is research like this that informs treatment progress and advancements.
  • The research published in Brain Stimulation follows the publication of registry data in the Journal of Affective Disorders in December 2020, which suggested NeuroStar Advanced Therapy be studied and evaluated as a first-line treatment for Major Depressive Disorder.

electroCore Announces Two-Year Extension of gammaCore™ Listing in the NHS Supply Chain Catalogue

Branches of biology, Anatomy, Neuroscience, ElectroCore, National Health Service, Vagus nerve, NHS Supply Chain
Tuesday, February 23, 2021 - 1:00pm

We are pleased that this extension will allow NHS trusts and healthcare organizations the option to continuously procure gammaCore Sapphire (nVNS) through the NHS Supply Chain online catalogue for an additional two years, stated Iain Strickland, Vice President of European Operations at electroCore.

Key Points: 
  • We are pleased that this extension will allow NHS trusts and healthcare organizations the option to continuously procure gammaCore Sapphire (nVNS) through the NHS Supply Chain online catalogue for an additional two years, stated Iain Strickland, Vice President of European Operations at electroCore.
  • Importantly, inclusion in this catalogue helps ensure gammaCore therapy is broadly accessible to patients across the UK who may benefit from non-invasive vagus nerve stimulation.
  • The role of the NHS Supply Chain is to help the NHS deliver clinically assured, quality products at the best value to its patients.
  • The inclusion of gammaCore in the catalogue allows hospitals to purchase gammaCore Sapphire for their primary headache patients, taking into account their own budgetary restrictions.

Nobody finds the Alzheimer's Germ in $1 Million Challenge, but eight researchers split $200K, says Dr. Leslie Norins of Alzheimer's Germ Quest

Branches of biology, Abnormal psychology, Alzheimer's disease, Dementia, Psychiatric diagnosis, Infection, Neuroscience, Psychiatry
Tuesday, February 23, 2021 - 11:10am

However, nobody provided persuasive-enough evidence that a particular infectious agent was the sole cause of Alzheimer's disease, so the grand prize of $1 million will not be awarded.

Key Points: 
  • However, nobody provided persuasive-enough evidence that a particular infectious agent was the sole cause of Alzheimer's disease, so the grand prize of $1 million will not be awarded.
  • The challenge initially attracted 81 would-be entrants, of whom 40 were authorized to submit formal entries.
  • Dr. Norins believes that plausible evidence submitted incriminating six different organisms means no one convincingly proved their nominee was the sole microbe triggering Alzheimer's disease.
  • Alzheimer's Germ Quest is an independent organization, not affiliated with any other group.

Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021

Health, Medical Supplies, Medical devices, Branches of biology, Neurotechnology, Neuroscience, Neuromodulation, Neurophysiology, Neuropsychology, Pain, Sacral nerve stimulation
Monday, February 22, 2021 - 9:01pm

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.

Key Points: 
  • Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.
  • In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.
  • Interested parties may access the live conference call by dialing 888-771-4371 (U.S.) or 847-585-4405 (International) and using passcode 50112306.
  • Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.